Human Resources Development Inst SW Opioid Treatment Program

Human Resources Development Inst SW Opioid Treatment Program is a SAMHSA-registered addiction-treatment facility located at Philadelphia, PA. The facility offers specific levels of care: Inpatient. Patient-level evaluation of this facility should distinguish three considerations: state licensure status, voluntary accreditation (CARF or Joint Commission), and clinical-framework alignment with current ASAM Criteria — each of which is independently verifiable.

Care levels at Human Resources Development Inst SW Opioid Treatment Program

The facility's documented care levels are The facility offers specific levels of care: Inpatient. — each of which is appropriate for specific clinical presentations. Matching the level to the specific clinical need is the pre-admission work. Operational prerequisite for admission: documented clinical assessment establishing medical necessity for the specific level of care Human Resources Development Inst SW Opioid Treatment Program provides. The ASAM Criteria 4e framework is the benchmark standard for this assessment and is referenced in most major payer medical-necessity documents.

Insurance and payment

Payment and insurance posture: Human Resources Development Inst SW Opioid Treatment Program accepts Medicaid — which is consequential because facilities that accept Medicaid tend to have the broadest patient populations and the most developed public-sector relationships, though reimbursement structures mean program intensity sometimes differs from commercial-focused centers. Pre-admission Verification of Benefits (VOB) documentation should include: specific plan product and network status, deductible status at time of admission, coinsurance rate applicable, prior authorization status and turnaround, and out-of-pocket accumulation. Under MHPAEA 2024 disclosure rules, plan-specific medical-necessity criteria must be available on request.

Specialty programming

The facility's documented specialty programming includes: Clients with co-occurring mental and substance use disorders. Clinical verification of specialty programming should encompass credentialed staff profile, programming-hour documentation, and specialty-specific medical-necessity documentation for third-party authorization. The MHPAEA 2024 rule addresses specialty-program network adequacy for patients requiring specific clinical capabilities.

Before you call

Pre-admission documentation for Human Resources Development Inst SW Opioid Treatment Program should include ASAM-framework level-of-care justification, plan-specific Verification of Benefits with network-contract confirmation, written MAT policy for opioid use disorder patients where applicable, and licensure/accreditation verification. If the clinical situation involves opioid use disorder, confirm explicitly whether Human Resources Development Inst SW Opioid Treatment Program offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.